Searched for
SUBSIDIARY SYNGENE INTERNATIONAL
Syngene International reports 11% revenue growth and 59% net profit surge in Q1Syngene International, a Biocon subsidiary, reveals an 11% revenue increase to Rs 875 crore for the first quarter. Net profit jumps 59% to ...- Stocks in news: City Union Bank, Navin Fluorine, Syngene, IIFL Finance, NLC India, Sharda Cropchem and Arvind FashionsWhen markets resume trading today, City Union Bank, Navin Fluorine, Syngene International, IIFL Finance, NLC India, Sharda Cropchem and Arv...
- Syngene can put on muscle as global pharma companies increase R&D spendingSyngene is a fully integrated CRAMS company and Biocon has around 70% stake in it. Syngene also has a wholly-owned subsidiary in the US.
- True North set to buy 8-10% stake in Anthem for Rs 740 crTrue North will acquire about 8-10 per cent stake in Anthem Biosciences for Rs 740 crore ($75-100 million), at a valuation of $1 billion (R...
- Biocon elevates M B Chinappa as CFO of biosimilar subsidiaryM B Chinappa, who is going to play an important role in Biocon Biologics’ journey towards becoming a global leader in biologics, has been t...
- GEPL Capital recommends 'subscribe' to Syngene International IPOSyngene International Ltd, a subsidiary of leading pharma major Biocon Ltd and India’s leading CRO, is planning to raise Rs 550 crore from ...
- Syngene IPO opens July 27; price band at Rs 240-250; Biocon shares end in redBiocon's subsidiary Syngene has set the price band for its forthcoming IPO at Rs 240-250 per share that will open on July 27.
- Plan to list Syngene in August, use IPO proceeds for R&D: Kiran Mazumdar-ShawSyngene International, present in the contract services business, had filed its draft red herring prospectus (DRHP) with Sebi .
- Syngene gets FIPB nod to raise foreign investment to 44%Syngene, a subsidiary of Biocon, said it has received the Foreign Investment Promotion Board approval to raise foreign investment to 44 per...
- Biocon arm Syngene appoints Peter Bains as CEOBains has been a director of Syngene, since 2011. Syngene had yesterday said it would set up a new plant at Mangalore SEZ to manufacture ph...
- Biocon arm to have 40-acre new plant in Mangalore SEZBiocon's research services arm Syngene International would set up a new plant at Mangalore SEZ to manufacture pharma ingredients.
- Biocon Q3 Net dips 13% to Rs 91 crore; to offload 10-15% in SyngeneBio-pharmaceuticals contributed Rs 541 crore and research services Rs 220 crore to revenue for the reporting quarter.
- Biocon completes 10 per cent stake sale in SyngeneBiotechnology major Biocon today concluded sale of 10 per cent stake in its research arm Syngene for Rs 380 crore to IVF Trustee Company Pr...
- Silver Leaf Oak to acquire 10% stake in Syngene International for Rs 380 croreThis transaction is part of the overall strategic plan for Syngene and sets a new benchmark as we prepare the company for listing, Kiran ad...
- Biocon rallies over 1% on buying stake in Syngene InternationalThe company, which had sold the stake to GE on October 31, 2012 for Rs 125 crore, has paid almost double to buy back this stake.
- Drug maker Biocon buys back GE Capital's stake in Syngene International for Rs 215 croreSyngene offers integrated drug discovery & development services with capabilities in medicinal chemistry, biology, in vivo pharmacology & t...
- Biocon’s unit extends partnership with US-based Bristol-Myers SquibbThe two cos announced to renew their engagement, boosted by encouraging results in last 5 years, during when 6 drug molecules have been bro...
- Biocon rules out listing of research services arm Syngene International this fiscalThe company, which was earlier working actively to list Syngene, said it will not happen this fiscal due to prevailing uncertainties.
- Biocon unit inks pact with US firm to expand collaborationBiotech firm Biocon today said its subsidiary 'Syngene International' has entered into an agreement with US-based Endo Pharmaceuticals to e...
- Biocon's Syngene, Bristol-Myers Squibb open new R&D unitWhile current global economic slowdown has prompted many companies to cut down on their R&D spends and/or suspend research on certain molec...
Load More
